John Kelly
Associate Professor / Consultant General Psychiatrist at Trinity College Dublin
Data updated
Research Footprint
John Kelly appears in 9 tracked papers (2020–2026), most studied alongside Psilocybin and 5-MeO-DMT, across Depressive Disorders, Treatment-Resistant Depression (TRD) and Major Depressive Disorder (MDD).
Most-cited paper: Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression (1057 citations).
Frequent co-authors: Veronica O'keane, Guy Goodwin and Tomáš Páleníček.
Background & Research
John R. Kelly is an Associate Professor of Psychiatry at Trinity College Dublin and a Consultant General Psychiatrist at Tallaght University Hospital. His research focuses on psychedelic science, systems psychiatry, and the clinical translation of psilocybin-assisted therapy. He is co-founder of the Trinity Psychedelic Research Group and has published on depression, service-user attitudes, and broader psychiatric applications of psychedelic therapy.
Key Impact
John R. Kelly is a leading academic psychiatrist in Ireland whose work has helped shape modern psychedelic psychiatry, including psilocybin research across depression, service-user attitudes, and transdiagnostic treatment frameworks.
Collaboration Network
33 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations John Kelly is associated with.
Psychedelic Resource Group, Trinity College Dublin
Non-ProfitThe Psychedelic Resource Group at Trinity College Dublin advances translational psychedelic research across psychiatry and neuroscience, with a focus on clinical applications, public-health integration, and evidence generation for psychedelic-assisted care.
View stakeholder →COMPASS Pathways
Public BiotechCOMPASS Pathways is a UK-listed biopharmaceutical company developing COMP360 synthetic psilocybin therapy for treatment-resistant depression, with two successful Phase 3 trials making it the leading candidate for the first regulatory approval of a classic psychedelic medicine.
View stakeholder →